Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.07, read 2026-10-28
Ethical passes the values gate
Price12.12 USD
Fair value9.82
Ethical score70.0/100
Our investment reviews on this name
2026-10-18Read Distribution12.27-1.2% to today ✓Markup gives way to Distribution
2026-10-11Read Markup12.15-0.2% to today Accumulation gives way to Markup first Markup read since August
2026-09-06Read Accumulation11.74+3.2% to today ✓Markup gives way to Accumulation after a 14% rise in 4 weeks
2026-08-06Read Markup10.27+18.0% to today ✓Markdown gives way to Markup after a 13% rise in 5 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Neogen Corporation holds its Distribution at $12.12. Elevated stress, defensive posture warranted, held for 5 days.
As held on the ledger · 2026-10-28
Phase
Distribution · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 5 days
Price at the screen
$12.12
Valuation
N/A trailing · 26.20 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.79
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
23.72%
Below 33%
Interest-bearing debt is just 23.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
9.93%
Below 49%
Money owed to the company is 9.9% of assets, under the 49% limit.
Pass
Revenue purity
0.35%
Below 5%
Only 0.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Neogen clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 24%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when NEOG's ethical verdict changes
Today NEOG passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. The price runs 18.9% above the base estimate.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Food Safety Tests Cannot Rescue Shrinking Profits
Picture a lab running tests on meat and milk to keep dinner tables safe. Neogen supplies those kits across food and animal segments, yet the business is shrinking. Revenue fell four percent last year while the company posted a seventy percent negative profit margin and negative twenty six percent return on equity. At ten dollars twenty seven cents the shares sit twenty eight percent above our fair value of seven dollars thirty five cents, so the opportunity rating stays at none despite an ethical screen pass.
The forward multiple of thirty four times earnings looks demanding for a firm that is losing money and showing no growth. Three analysts carry a twelve dollar median target, but that does not change the gap between price and our calculated worth. Unknown competitive moat adds another layer of uncertainty around whether the product range can regain traction.
High valuation paired with losses leaves little margin for error if demand stays soft or currency moves hit international sales. The ethical clearance removes one concern, yet the numbers still point to an overpriced business with no clear path back to profits. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
NEOG trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-25Distribution$11.79-3.9%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (3 analysts) rates it none, with a mean price target of $12. Insiders have been net buyers over the past quarter. Since the last review it its composite score rose.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 1.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (3 analysts) rates it none, with a mean price target of $12. Insiders have been net buyers over the past quarter.
2026-10-11Markup · changed$12.15-10.7%Entry 7
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 10.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 19% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (3 analysts) rates it none, with a mean price target of $12.
2026-10-02Accumulation$13.61+15.9%Entry 6
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 15.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 19% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (3 analysts) rates it none, with a mean price target of $12. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 14.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 19% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (3 analysts) rates it none, with a mean price target of $12.
2026-08-06Markup · changed$10.27+12.9%Entry 4
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 19% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (3 analysts) rates it none, with a mean price target of $12.
2026-07-18Markdown$9.10+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 19% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (3 analysts) rates it none, with a mean price target of $12.
2026-07-03Markdown$9.10+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markdown$9.10Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
